---
title: "Nilotinib - Chronic phase chronic myeloid leukemia"
sidebar: mydoc_sidebar
permalink: db04868-mesh-d015466-1.html
toc: false 
---


Path ID: `DB04868_MESH_D015466_1`
{% include image.html url="images/db04868-mesh-d015466-1.png" file="db04868-mesh-d015466-1.png" alt="db04868-mesh-d015466-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:C498826 | nilotinib | Drug |
| UniProt:P00519 | Tyrosine-protein kinase ABL1 | Protein |
| MESH:D016044 | Fusion Proteins, bcr-abl | Protein |
| GO:0004674 | protein serine/threonine kinase activity | MolecularActivity |
| GO:0007266 | Rho protein signal transduction | BiologicalProcess |
| GO:0008283 | cell population proliferation | BiologicalProcess |
| GO:0006915 | apoptotic process | BiologicalProcess |
| MESH:D015466 | Chronic phase chronic myeloid leukemia | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Nilotinib | DECREASES ACTIVITY OF | Tyrosine-Protein Kinase Abl1 |
| Tyrosine-Protein Kinase Abl1 | PARTICIPATES IN | Fusion Proteins, Bcr-Abl |
| Fusion Proteins, Bcr-Abl | POSITIVELY REGULATES | Protein Serine/Threonine Kinase Activity |
| Protein Serine/Threonine Kinase Activity | POSITIVELY CORRELATED WITH | Rho Protein Signal Transduction |
| Rho Protein Signal Transduction | POSITIVELY CORRELATED WITH | Cell Population Proliferation |
| Rho Protein Signal Transduction | NEGATIVELY CORRELATED WITH | Apoptotic Process |
| Cell Population Proliferation | POSITIVELY CORRELATED WITH | Chronic Phase Chronic Myeloid Leukemia |
| Apoptotic Process | NEGATIVELY CORRELATED WITH | Chronic Phase Chronic Myeloid Leukemia |
|---------|-----------|---------|

Reference: 
  - [https://go.drugbank.com/drugs/DB04868#BE0000014](https://go.drugbank.com/drugs/DB04868#BE0000014)
  - [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4004101/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4004101/)
